Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 48,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Bypass Grafting
Interventions: Vein Harvesting Procedures; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • San Francisco, California • Gainesville, Florida + 13 more

Conditions: Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
Interventions: Tacrolimus, Sirolimus, Bortezomib; Drug
Lead sponsor: Jennifer E. Schwartz; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
Interventions: Cisplatin, Cixutumumab, Etoposide, Laboratory Biomarker Analysis, Vismodegib; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 301
States / cities: Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more

Conditions: Alcohol Dependence
Interventions: Prazosin Tablet, Placebo Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Enhanced NCP Support, LEAP; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Perforated Appendicitis
Interventions: IV tylenol, No IV tylenol, Ketorolac; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Coronary Artery Disease
Interventions: FFRangio; Device
Lead sponsor: CathWorks Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Roslyn, New York + 1 more

Conditions: Cancer Survivor
Interventions: education, nutrition intervention, exercise intervention, questionnaire administration, laboratory biomarker analysis, quality-of-life assessment; Other · Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: NSCLC
Interventions: Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection; Device · Drug · Other
Lead sponsor: Galvanize Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Transplant; Failure, Kidney
Interventions: Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids; Drug
Lead sponsor: Gaetano Ciancio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: CO-1.01, Gemcitabine; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 21
States / cities: Glendale, Arizona • Corona, California • Los Angeles, California + 17 more

Conditions: Multiple Sclerosis, Gait Disorders, Neurologic
Interventions: Ekso GT™ exoskeleton; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HRD Cancer, SCLC, Advanced Solid Tumors
Interventions: Berzosertib, Sacituzumab Govitecan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sedentary Lifestyle, Obesity
Interventions: Social walking intervention; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PTSD - Post Traumatic Stress Disorder
Interventions: Low diversity plant beverage (Functional Food Intervention), High diversity plant beverage (Functional Food Intervention); Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Bleeding Disorders, Iron, Platelet, Bleeding
Interventions: IV Iron (standard of care); Drug
Lead sponsor: Nicoletta C Machin; Other
Eligibility: 15 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Suicide, Attempted, Suicide, Ideation, Depression, Substance Abuse
Interventions: CBT-RP (relapse prevention) + Enhanced TAU, Enhanced TAU Alone; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 13 Years to 19 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Kidney Diseases
Interventions: Exercise, Stretching; Behavioral
Lead sponsor: University of North Texas, Denton, TX; Other
Eligibility: 30 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Lung Transplant Infection
Interventions: Inhaled beclomethasone, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Surgery, Anesthesia
Interventions: Haider ETT Tube Holder and Bite Guard, Tape; Device · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Obstructive Sleep Apnea of Adult
Interventions: Automatic Positive Airway Pressure (APAP); Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer

Randomized Endo-Vein Graft Prospective

A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

Learn, Engage, Act, Process (LEAP) for MOVE!

The Impact of IV Acetaminophen on Pain After Appendectomy for Perforated Appendicitis

FFRangio Accuracy vs. Standard FFR

Harvesting Health Program in Improving Diet and Physical Activity Level in Cancer Survivors

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Testing Strategies for Increasing Exercise

Diet and Microbiome Interactions: Application in Posttraumatic Stress Disorder in Adults Consuming Vegetable Drinks

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders

Relapse Prevention for Suicidal Dually Diagnosed Youths

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Cerebrovascular Dysregulation in Chronic Kidney Disease

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

Endotracheal Tube Holder and Bite Guard Research

Obstructive Sleep Apnea Treatment in Serious Mental Illness